Our Principal, Yolanda Wang, just returned from the 1st China Pharmaceutical Innovation Conference (CPIC 2026) in Shanghai, held from July 22–24!

It was a pleasure to attend CPIC 2026 together with fellow HKBMIA members and connect with biotech innovators from around the world. Many thanks to HKBMIA for the invitation and the opportunity to engage with industry partners. Hong Kong continues to play an important role in connecting Mainland China with the global life sciences community.

Bringing together over 10,000 participants, CPIC highlighted the strong momentum behind cross-border biopharma innovation and collaboration. It was great to see so many discussions focused on advancing healthcare innovation and building new partnerships across borders. The strong presence of AI-related healthcare and drug development initiatives was particularly impressive and reflected the rapid evolution of China’s innovation ecosystem. As IP professionals, we are reminded of the important role that IP plays in supporting innovation and bringing new technologies to market.

Our Past Events

Recommended Insights

China Patent 2020 to 2021

China Provides Specific Directions to Strengthen Patent / Technology Protection from 2020 to 2021

23 April 2020
China continues to progress towards its major goal of significantly strengthening IP protection within its borders. Last year it announced several proposed amendments to its patent laws. In January 2020 China and the US signed the Economic and Trade Agreement between the Government of China and US (published 16 January 2020 –“Trade Agreement”), which detailed […]

Markush claims in China - what can be arbitrarily deleted during invalidation?

4 December 2018
Since 2010, the China Patent Re-examination Board (PRB) has published the top 10 patent invalidation cases of the year in April of each year. The selection criteria are high social concern, significant impact on the related industry, or involve difficult legal issues and important examination criteria. Below is one of the top 10 cases that […]

China Divisional Practice

17 June 2019
China allows the filing of divisional applications but under specific circumstances. Most importantly, divisional applications can usually only be filed voluntarily during the prosecution of the original parent application. Once the parent application is granted or withdrawn, no additional voluntary divisional applications may be filed. However, divisionals can be filed to pursue subject matter not […]

China’s Supreme People’s Court (SPC) Hands Down First Patent Linkage Appeal Decision

21 September 2022
China has been implementing a plethora of new laws and measures that are particularly favorable to drug companies, such as patent term extension and patent linkage.  Details of the new implementation measures for patent linkage (technically “early dispute resolution mechanisms for drug patents”) came into effect on July 4, 2021. At around the same time, […]
Top crossarrow-right